Israel - heprea - Ministry of Health

padagis israel pharmaceuticals ltd, israel - alprazolam - טבליה - alprazolam 0.5 mg - alprazolam - alprazolam - treatment of anxiety accompanied by depression. treatment of panic states with or without accompanying phobia.

Israel - heprea - Ministry of Health

padagis israel pharmaceuticals ltd, israel - alprazolam - טבליה - alprazolam 1 mg - alprazolam - alprazolam - treatment of anxiety accompanied by depression. treatment of panic states with or without accompanying phobia.

Israel - heprea - Ministry of Health

padagis israel pharmaceuticals ltd, israel - alprazolam - טבליה - alprazolam 0.25 mg - alprazolam - alprazolam - treatment of anxiety accompanied by depression. treatment of panic states with or without accompanying phobia.

Israel - heprea - Ministry of Health

teva pharmaceutical industries ltd, israel - amitriptyline hydrochloride - טבליה - amitriptyline hydrochloride 10 mg - amitriptyline - amitriptyline - for the relief of symptoms of depression. endogenous depression is more likely to be alleviated than other depressive states. enuresis nocturna.

Israel - heprea - Ministry of Health

teva pharmaceutical industries ltd, israel - amitriptyline hydrochloride - טבליה - amitriptyline hydrochloride 25 mg - amitriptyline - amitriptyline - relief of symptoms of depression.endogenous depression is more likely to be alleviated than are other depressive states.enuresis nocturna.

Israel - heprea - Ministry of Health

rekah pharmaceutical industry ltd, israel - lithium carbonate - טבליה - lithium carbonate 300 mg - lithium - treatment of manic depressive states.

Israel - heprea - Ministry of Health

novartis pharma services ag - clozapine 25 mg - tablets - clozapine - treatment of resistant schizophrenic patients who are non-responsive to, or intolerant of classic neuroleptics. reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder who are judged to be at chronic risk for re-experiencing suicidal behavior, based on history and recent clinical state. suicidal behavior refers to actions by a patient that put him/herself at risk for death.

Israel - heprea - Ministry of Health

novartis pharma services ag - clozapine 100 mg - tablets - diazepines, oxazepines, thiazepines and oxepines - for treatment in resistant schizoprenic patients who are non-responsive to, or intolerant to classical neuroleptics. reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder who are judged to be at chronic risk for re-experiencing suicidal behavior, based on history and recent clinical state. suicidal behavior refers to actions by a patient that put him/herself at risk for diath.

Israel - heprea - Ministry of Health

novartis pharma services ag - metformin hydrochloride 850 mg; vildagliptin 50 mg - film coated tablets - metformin - eucreas is indicated in the treatment of type 2 diabetes mellitus:• eucreas is indicated in the treatment of type 2 diabetes patients who are unable to achieve sufficient glycemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets.• eucreas is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled with metformin and a sulphonylurea.• eucreas is indicated in triple combination therapy with insulin as an adjunct to diet and exercise to improve glycaemic control in patients when insulin at a stable dose and metformin alone do not provide adequate glycaemic control.

Israel - heprea - Ministry of Health

novartis pharma services ag - vildagliptin 50 mg - tablets - vildagliptin - galvus is indicated as an adjunct to diet and exercise in patients with type 2 diabetes mellitus• as monotherapy, if diet and exercise are not sufficient, or• in combination with metformin, or a sulfonylurea if treatment with these oral antidiabetics does not offer sufficient control of blood glucose.as triple oral therapy in combination with• a sulphonylurea and metformin when diet and exercise plus dual therapy with these agents do not provide adequate glycaemic control. galvus is also indicated for use in combination with insulin (with or without metformin) when diet and exercise plus a stable dose of insulin do not provide adequate glycaemic control.